News Archive

Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract valued at up to approximately $25 million by the U.S. Department of State to supply TROBIGARD™ (Atropine Sulfate [2mg]/Obidoxime Chloride [220mg]) auto-injector, a drug and device combination product for emergency use in the event of nerve agent or organophosphate poisoning. Trobigard is designed for intramuscular self- or buddy-administration of atropine sulfate and obidoxime chloride for pre-hospital intervention.  

A digital health report from Rock Health showed that women-led companies and geographic diversity continued to build in the third quarter. In the three months through September 30, of the 84 companies that raised $1.2 billion, 16 percent were led by women.

When it comes to high-tech startups, we hear a lot about the so-called “rise of the rest.” As the nation’s leading centers of high-tech industry—places like the San Francisco Bay Area, New York City, Boston, and Seattle—have become increasingly expensive to live in, the argument goes, talented techies, entrepreneurs, and startups are moving to less expensive places like Portland, Pittsburgh, Detroit, Nashville, Las Vegas, and others.

Qiagen has announced that its manufacturing and supply chain for consumables and other products for forensic and human identity testing has been certified by Bureau Veritas, a leading inspection agency, as meeting the latest international standards for products used in forensic testing.

Despite the jurisdictional posturing in Maryland, Virginia and Washington D.C. over a possible Amazon headquarters, a new FBI building or a national football stadium, the recent joint trade mission to Canada by their respective leaders — along with efforts such as the Greater Washington Board of Trade holding its summit at the Pendry Hotel in Baltimore — all augur well for better regional cooperation.

BioMarker Strategies, LLC today announced that the National Cancer Institute (NCI) has awarded the Company a Phase I Small Business Innovation Research (SBIR) grant for development of a pathway-based companion diagnostic test to identify patients with head and neck squamous cell carcinoma (HNSCC) who are most likely to respond to treatment with cetuximab. The grant will provide $299,000 in research support.

WellDoc®, a leading digital health company, announced today the appointment of Laurel Pickering, president and CEO of Northeast Business Group on Health (NEBGH), as the Company’s new Chief Revenue Officer (CRO). Ms. Pickering selected WellDoc as her next opportunity after spending nearly 25 years at the helm of NEBGH, an employer-led coalition of healthcare leaders and other stakeholders. Ms. Pickering will join the WellDoc team in October.

Three prominent Chinese executives discuss the progress of local companies in drug innovation and the evolving regulatory environment.

Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed its acquisition of raxibacumab, a fully human monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment and prophylaxis of inhalational anthrax, from GSK (LSE:GSK) (NYSE:GSK). With the acquisition, Emergent also plans to assume responsibility for a multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA), valued at up to approximately $130 million to supply the product to the U.S. Strategic National Stockpile (SNS) through November 2019. The completion of the acquisition follows the satisfaction or waiver by the parties, as applicable, of all closing conditions, including expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended.

Effective September 26, 2017, the Board of Directors (the “Board”) of Sorrento Therapeutics, Inc. (Nasdaq: SRNE) appointed each of Dorman Followwill and David Lemus as an independent director of the Company.